The use of acetazolamide during pregnancy in intracranial hypertension patients

Julie Falardeau, Brenna M. Lobb, Sara Golden, Steven D. Maxfield, Emanuel Tanne

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Acetazolamide is the mainstay of medical therapy for idiopathic intracranial hypertension (IIH). Its use in pregnant women has not been recommended because of reported teratogenic effects in rodents and rabbits. However, the safety of acetazolamide use during human pregnancy remains unclear. We report the pregnancy and offspring outcomes in women with intracranial hypertension (IH) treated with acetazolamide during pregnancy. Methods: Data were collected through questionnaires sent to patients with IH and their physicians. The questionnaires focused on IH diagnosis, obstetric history and outcomes, and pediatric outcomes. Results: A total of 101 women with IH were consented (total of 158 pregnancies) and acetazolamide usage before 13 weeks of gestation was reported in 50 pregnancies. The risk of spontaneous abortion was similar to the control group and no major complication was identified in the offspring of women treated with acetazolamide. Conclusion: There is no convincing evidence for an adverse effect for acetazolamide use in human pregnancy, even when prescribed prior to the 13th week of gestation. While the liberal use of acetazolamide should be avoided during pregnancy, this medication should remain a treatment option in pregnant women when clinically indicated.

Original languageEnglish (US)
Pages (from-to)9-12
Number of pages4
JournalJournal of Neuro-Ophthalmology
Volume33
Issue number1
DOIs
StatePublished - Mar 2013

Fingerprint

Acetazolamide
Intracranial Hypertension
Pregnancy
Pregnant Women
Pseudotumor Cerebri
Spontaneous Abortion
Pregnancy Outcome
Obstetrics
Rodentia
History
Pediatrics
Rabbits
Physicians
Safety
Control Groups
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Ophthalmology

Cite this

The use of acetazolamide during pregnancy in intracranial hypertension patients. / Falardeau, Julie; Lobb, Brenna M.; Golden, Sara; Maxfield, Steven D.; Tanne, Emanuel.

In: Journal of Neuro-Ophthalmology, Vol. 33, No. 1, 03.2013, p. 9-12.

Research output: Contribution to journalArticle

Falardeau, Julie ; Lobb, Brenna M. ; Golden, Sara ; Maxfield, Steven D. ; Tanne, Emanuel. / The use of acetazolamide during pregnancy in intracranial hypertension patients. In: Journal of Neuro-Ophthalmology. 2013 ; Vol. 33, No. 1. pp. 9-12.
@article{211462e59f114eabbd799948876c75f5,
title = "The use of acetazolamide during pregnancy in intracranial hypertension patients",
abstract = "Background: Acetazolamide is the mainstay of medical therapy for idiopathic intracranial hypertension (IIH). Its use in pregnant women has not been recommended because of reported teratogenic effects in rodents and rabbits. However, the safety of acetazolamide use during human pregnancy remains unclear. We report the pregnancy and offspring outcomes in women with intracranial hypertension (IH) treated with acetazolamide during pregnancy. Methods: Data were collected through questionnaires sent to patients with IH and their physicians. The questionnaires focused on IH diagnosis, obstetric history and outcomes, and pediatric outcomes. Results: A total of 101 women with IH were consented (total of 158 pregnancies) and acetazolamide usage before 13 weeks of gestation was reported in 50 pregnancies. The risk of spontaneous abortion was similar to the control group and no major complication was identified in the offspring of women treated with acetazolamide. Conclusion: There is no convincing evidence for an adverse effect for acetazolamide use in human pregnancy, even when prescribed prior to the 13th week of gestation. While the liberal use of acetazolamide should be avoided during pregnancy, this medication should remain a treatment option in pregnant women when clinically indicated.",
author = "Julie Falardeau and Lobb, {Brenna M.} and Sara Golden and Maxfield, {Steven D.} and Emanuel Tanne",
year = "2013",
month = "3",
doi = "10.1097/WNO.0b013e3182594001",
language = "English (US)",
volume = "33",
pages = "9--12",
journal = "Journal of Neuro-Ophthalmology",
issn = "1070-8022",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The use of acetazolamide during pregnancy in intracranial hypertension patients

AU - Falardeau, Julie

AU - Lobb, Brenna M.

AU - Golden, Sara

AU - Maxfield, Steven D.

AU - Tanne, Emanuel

PY - 2013/3

Y1 - 2013/3

N2 - Background: Acetazolamide is the mainstay of medical therapy for idiopathic intracranial hypertension (IIH). Its use in pregnant women has not been recommended because of reported teratogenic effects in rodents and rabbits. However, the safety of acetazolamide use during human pregnancy remains unclear. We report the pregnancy and offspring outcomes in women with intracranial hypertension (IH) treated with acetazolamide during pregnancy. Methods: Data were collected through questionnaires sent to patients with IH and their physicians. The questionnaires focused on IH diagnosis, obstetric history and outcomes, and pediatric outcomes. Results: A total of 101 women with IH were consented (total of 158 pregnancies) and acetazolamide usage before 13 weeks of gestation was reported in 50 pregnancies. The risk of spontaneous abortion was similar to the control group and no major complication was identified in the offspring of women treated with acetazolamide. Conclusion: There is no convincing evidence for an adverse effect for acetazolamide use in human pregnancy, even when prescribed prior to the 13th week of gestation. While the liberal use of acetazolamide should be avoided during pregnancy, this medication should remain a treatment option in pregnant women when clinically indicated.

AB - Background: Acetazolamide is the mainstay of medical therapy for idiopathic intracranial hypertension (IIH). Its use in pregnant women has not been recommended because of reported teratogenic effects in rodents and rabbits. However, the safety of acetazolamide use during human pregnancy remains unclear. We report the pregnancy and offspring outcomes in women with intracranial hypertension (IH) treated with acetazolamide during pregnancy. Methods: Data were collected through questionnaires sent to patients with IH and their physicians. The questionnaires focused on IH diagnosis, obstetric history and outcomes, and pediatric outcomes. Results: A total of 101 women with IH were consented (total of 158 pregnancies) and acetazolamide usage before 13 weeks of gestation was reported in 50 pregnancies. The risk of spontaneous abortion was similar to the control group and no major complication was identified in the offspring of women treated with acetazolamide. Conclusion: There is no convincing evidence for an adverse effect for acetazolamide use in human pregnancy, even when prescribed prior to the 13th week of gestation. While the liberal use of acetazolamide should be avoided during pregnancy, this medication should remain a treatment option in pregnant women when clinically indicated.

UR - http://www.scopus.com/inward/record.url?scp=84874056824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874056824&partnerID=8YFLogxK

U2 - 10.1097/WNO.0b013e3182594001

DO - 10.1097/WNO.0b013e3182594001

M3 - Article

C2 - 22635167

AN - SCOPUS:84874056824

VL - 33

SP - 9

EP - 12

JO - Journal of Neuro-Ophthalmology

JF - Journal of Neuro-Ophthalmology

SN - 1070-8022

IS - 1

ER -